Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Andrea Aiello; Anna D’Ausilio; Roberta Lo Muto; Francesca Randon; Luca Laurenti

doi:10.1080/20016689.2017.1393308

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Andrea Aiello^*, Anna D’Ausilio, Roberta Lo Muto, Francesca Randon, Luca Laurenti

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	JOURNAL OF MARKET ACCESS & HEALTH POLICY
Volume	5
DOI	https://doi.org/10.1080/20016689.2017.1393308
Stato di pubblicazione	Pubblicato - 2017

Keywords

Italy
Waldenström Macroglobulinemia
cost-effectiveness analysis
ibrutinib

Accesso al documento

10.1080/20016689.2017.1393308

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{2baa781b47054d7d8086490fce6a305c,

title = "Cost-effectiveness analysis of ibrutinib in patients with Waldenstr{\"o}m macroglobulinemia in Italy",

abstract = "Ibrutinib has recently been approved in Europe for Waldenstr{\"o}m Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).",

keywords = "Italy, Waldenstr{\"o}m Macroglobulinemia, cost-effectiveness analysis, ibrutinib, Italy, Waldenstr{\"o}m Macroglobulinemia, cost-effectiveness analysis, ibrutinib",

author = "Andrea Aiello and Anna D{\textquoteright}Ausilio and {Lo Muto}, Roberta and Francesca Randon and Luca Laurenti",

year = "2017",

doi = "10.1080/20016689.2017.1393308",

language = "English",

volume = "5",

pages = "N/A--N/A",

journal = "JOURNAL OF MARKET ACCESS & HEALTH POLICY",

issn = "2001-6689",

publisher = "J{\"a}rf{\"a}lla: Co-Action Publishing, 2013-",

}

TY - JOUR

T1 - Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

AU - Aiello, Andrea

AU - D’Ausilio, Anna

AU - Lo Muto, Roberta

AU - Randon, Francesca

AU - Laurenti, Luca

PY - 2017

Y1 - 2017

N2 - Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

AB - Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the incremental cost-effectiveness ratio (ICER) of ibrutinib in relapse/refractory WM, compared with the Italian current therapeutic pathways (CTP).

KW - Italy

KW - Waldenström Macroglobulinemia

KW - cost-effectiveness analysis

KW - ibrutinib

KW - Italy

KW - Waldenström Macroglobulinemia

KW - cost-effectiveness analysis

KW - ibrutinib

UR - http://hdl.handle.net/10807/135397

U2 - 10.1080/20016689.2017.1393308

DO - 10.1080/20016689.2017.1393308

M3 - Article

SN - 2001-6689

VL - 5

SP - N/A-N/A

JO - JOURNAL OF MARKET ACCESS & HEALTH POLICY

JF - JOURNAL OF MARKET ACCESS & HEALTH POLICY

ER -

Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo